CA2345753A1 - A method to increase the excretion of non-sterol endogenous hydrophobic substances by increasing excretion of fat via the faeces - Google Patents

A method to increase the excretion of non-sterol endogenous hydrophobic substances by increasing excretion of fat via the faeces Download PDF

Info

Publication number
CA2345753A1
CA2345753A1 CA002345753A CA2345753A CA2345753A1 CA 2345753 A1 CA2345753 A1 CA 2345753A1 CA 002345753 A CA002345753 A CA 002345753A CA 2345753 A CA2345753 A CA 2345753A CA 2345753 A1 CA2345753 A1 CA 2345753A1
Authority
CA
Canada
Prior art keywords
compound
excretion
fat
accumulation
faeces
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002345753A
Other languages
English (en)
French (fr)
Inventor
Hendrik Jan Verkade
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2345753A1 publication Critical patent/CA2345753A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002345753A 1999-07-30 1999-07-30 A method to increase the excretion of non-sterol endogenous hydrophobic substances by increasing excretion of fat via the faeces Abandoned CA2345753A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/NL1999/000492 WO2001008679A1 (en) 1999-07-30 1999-07-30 A method to increase the excretion of non-sterol endogenous hydrophobic substances by increasing excretion of fat via the faeces

Publications (1)

Publication Number Publication Date
CA2345753A1 true CA2345753A1 (en) 2001-02-08

Family

ID=19866607

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002345753A Abandoned CA2345753A1 (en) 1999-07-30 1999-07-30 A method to increase the excretion of non-sterol endogenous hydrophobic substances by increasing excretion of fat via the faeces

Country Status (5)

Country Link
EP (1) EP1117396A1 (de)
JP (1) JP2003505504A (de)
AU (1) AU5200299A (de)
CA (1) CA2345753A1 (de)
WO (1) WO2001008679A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1216625A1 (de) * 2000-12-21 2002-06-26 The Procter & Gamble Company Verwendung eines unverdaulichen nicht-absorbierbaren Lipids zur Behandlung der Hyperbilirubinämie
ME02070B (me) 2004-03-05 2013-10-31 Univ Pennsylvania Postupci za lečenje poremećaja ili bolesti povezanih sa hiperlipidemijom i hiperholesterolemijom uz minimizaciju sporednih efekata
WO2013070856A1 (en) * 2011-11-09 2013-05-16 Denovo Inc. Toxin decontaminant food product and method of treating disorders of the gastrointestinal tract

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4363801A (en) * 1981-02-09 1982-12-14 The Texas A&M University System Method for treating hyperbilirubinemia
AU570143B2 (en) * 1985-01-14 1988-03-03 Rockefeller University, The Method of increasing heme excretion from a mammal using tin protoporphyrin
WO1989006137A1 (en) * 1988-01-11 1989-07-13 Massachusetts Institute Of Technology Oral bilirubin therapy
US5665775A (en) * 1995-07-28 1997-09-09 Arab Pharmaceutical Manufacturing Co., Ltd. Different way of management of neonatal hyperbilirubinemia
JPH10330265A (ja) * 1997-06-02 1998-12-15 Lederle Japan Ltd 肝疾患治療剤

Also Published As

Publication number Publication date
AU5200299A (en) 2001-02-19
EP1117396A1 (de) 2001-07-25
JP2003505504A (ja) 2003-02-12
WO2001008679A1 (en) 2001-02-08

Similar Documents

Publication Publication Date Title
US20200297625A1 (en) Dimethyl sulfoxide (dmso) and methylsulfonylmethane (msm) formulations to treat osteoarthritis
US11331302B2 (en) Transmucosal delivery of tocotrienol
US20080234362A1 (en) Treatment for Asthma and Arthritis and Other Inflammatory Diseases
US5230996A (en) Use of ascorbate and tranexamic acid solution for organ and blood vessel treatment prior to transplantation
AU2004210244B2 (en) Oils enriched with diacylglycerols and phytosterol esters for use in the reduction of cholesterol and triglycerides
Ullrich Evaluation of a high-fiber diet in hyperlipidemia: a review.
KR20070040371A (ko) 혈장 지질을 낮추기 위한 알파 케토글루타레이트 및 관련화합물의 용도
AU679818B2 (en) Butyric ester cyto-differentiating agents
CA2345753A1 (en) A method to increase the excretion of non-sterol endogenous hydrophobic substances by increasing excretion of fat via the faeces
Sirtori et al. Mechanisms of lipid-lowering agents
Lukovac et al. Gelucire® 44/14 improves fat absorption in rats with impaired lipolysis
KR100304312B1 (ko) 아연이보충된전립선추출물
Geremias et al. Lipid lowering activity of hydrosoluble chitosan and association with Aloe vera L. and Brassica olearaceae L.
US6476010B2 (en) Method for increasing intestinal absorption of fat soluble vitamins in post-menopausal women and lower animals
US5942500A (en) Dietary composition to reduce dietary fats
US20030133965A1 (en) Application of phytosterols (and their isomers), folic acid, cyanocobalamin and pyridoxin in dietetic (alimentary) fibers
AU2001249106A1 (en) Method for increasing intestinal absorption of fat soluble vitamins in post-menopausal women and lower animals
EP0354818A2 (de) Polyaromatische Verbindungen als Wirkstoffe enthaltende pharmazeutische Zusammensetzungen und Verwendung davon
US6998397B2 (en) Method for decreasing cholesterol level in blood
CA1117041A (fr) Complexe lipoproteique normalisant l'efficacite de la vitamine e et des antioxydants de synthese
Hsiang et al. Intraluminal endothelium-covered bridges in chronic fat-fed balloon-injured Yucatan miniswine
CH635749A5 (en) Lipoprotein complex which regularises the efficacy of vitamin E and synthetic antioxidants
WO2008101923A1 (en) Use of pantothenic acid derivatives for the treatment of hypophosphatemia
WO2014042448A1 (ko) 포스파티딜콜린 및 바이페닐—디메틸-디카르복실레이트를 포함하는 간 질환 예방 또는 치료용 조성물 및 이의 용도
ZA200207235B (en) Method for increasing intestinal absorption of fat soluble vitamins in post-menopausal women and lower animals.

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20050801